Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study by Bolanowski, Marek et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0423-104X
e-ISSN: 2299-8306
Quality of life in patients with acromegaly receiving lanreotide
autogel: a real-world observational study
Authors:  Marek Bolanowski, Alicja Hubalewska-Dydejczyk, Beata Kos-Kudła,
Marek Ruchała, Przemysław Witek, Wojciech Zgliczyński, Aude Houchard, Marta
Bartmańska
DOI: 10.5603/EP.a2021.0075




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Endokrynologia Polska" are listed in PubMed.
The final version may contain major or minor changes. 
Powered by TCPDF (www.tcpdf.org)
Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world 
observational study
Running title: Lanreotide autogel and QoL in acromegaly
10.5603/EP.a2021.0075
Marek Bolanowski1, Alicja Hubalewska-Dydejczyk2, Beata Kos-Kudła3, Marek Ruchała4, 
Przemysław Witek5, Wojciech Zgliczyński6, Aude Houchard7, Marta Bartmańska8
1Department of Endocrinology, Diabetes, and Isotope Therapy, Medical University, Wroclaw, 
Poland
2Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland
3Department of Endocrinology and Neuroendocrine Tumours, ENETS Centre of Excellence,
Department of Pathophysiology and Endocrinology, Medical University of Silesia, 
Katowice, Poland
4Department of Endocrinology, Metabolism, and Internal Diseases, University of Medical 
Sciences, Poznan, Poland
5Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of 
Warsaw, Poland
6Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland
7Ipsen, Boulogne-Billancourt Cedex, France 
8Ipsen, Warsaw, Poland
Corresponding author
Marta Bartmańska, Medical Advisor Ipsen Poland sp. z o.o., ul. Chmielna 73, Warszawa 00–
801, tel: (+48) 505 168 934, (+48) 22 653 68 00; e-mail: marta.bartmanska@ipsen.com
Abstract
Introduction: Patients with acromegaly have substantially reduced quality of life (QoL). This
study evaluated QoL in patients with acromegaly treated with lanreotide autogel.
Material and methods: This was a prospective, non-interventional, observational, multi-
centre study conducted in Poland (NCT02396966). We included patients with acromegaly, 
who received treatment with lanreotide autogel 120 mg for ≥ 3 months and < 3 years. Patients
were assessed approximately every 4–5 months for two years (six visits). QoL was measured 
with the Acromegaly Quality of Life Questionnaire (AcroQoL).
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Results: Of 152 patients enrolled from November 2014 to May 2018 in 37 centres, 24 were 
excluded due to major protocol deviations. The results are reported for the study population (n
= 128). At baseline, the median (95% confidence interval [CI]) time from diagnosis was 3.3 
(2.8, 4.2) years, and the median time since lanreotide initiation was 13.4 (9.9, 17.3) months. 
Symptoms of acromegaly were present at baseline in 86% of patients (headache, 57%; 
sweating, 58%; joint symptoms, 64%); symptoms remained unchanged at two years in 82% of
patients. At baseline, 27% of patients had hormonal control (growth hormone < 2.5 μg/L and 
insulin-like growth factor-1 within the normal range); hormonal control status did not change 
during the study period in over 81% of patients. At baseline, 88% of patients were either very 
satisfied or satisfied with treatment; treatment satisfaction was unchanged in 62% of patients 
over the study period. Mean (95% CI) AcroQoL scores at baseline were as follows: total, 50.3
(47.3, 53.3); physical dimension, 48.8 (45.2, 52.4); psychological dimension, 51.3 (48.2, 
54.4); appearance subdimension, 40.7 (37.5, 43.8); and personal relations subdimension, 62.5 
(58.8, 66.2). The psychological appearance subscore improved by 3.8 points (1.2, 6.5) over 
the two years; scores in the remaining dimensions and subdimensions did not change 
substantially. The total AcroQoL score remained unchanged over the two years, regardless of 
prior acromegaly treatment, surgery or radiotherapy, hormonal control, or lanreotide dosing 
interval. No new safety findings were identified.
Conclusions: AcroQoL total scores and physical and psychological subscores remained stable
but impaired among patients with long-lasting acromegaly treated with lanreotide autogel for 
two years. The psychological appearance subdimension improved numerically.
Key words: acromegaly; somatostatin analogue; lanreotide, quality of life; AcroQoL
Introduction
Acromegaly is caused by an excessive secretion of growth hormone (GH), typically by a 
pituitary adenoma, with a consequent increase in the production of insulin-like growth factor-
1 (IGF-1) [1]. The symptoms and complications of acromegaly include acral enlargement, 
facial disfiguration, arthralgia and arthritis, headache, sleep apnoea, cardiovascular diseases, 
and disorders of glucose metabolism [1]. Acromegaly worsens both the physical and 
emotional well-being of patients, and substantially reduces quality of life (QoL) at all disease 
stages [2]. Patients with acromegaly have much lower scores on generic questionnaires 
measuring QoL compared to the general population or patients with other chronic diseases, 
such as asthma, angina, and osteoarthritis [3–5]. The physical aspect of QoL in acromegaly is 
substantially affected by pain, weakness, sleep problems, and limitations of daily activities
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[6]. The psychological aspect of QoL in acromegaly is worsened by a negative perception of 
one’s appearance and difficulties in personal relations [6].
The first-line treatment for most patients with acromegaly is transsphenoidal resection of the 
adenoma, whereas pharmacological treatment is given to those who have uncontrolled disease
after surgery or contraindications to surgery [7,8]. Long-acting somatostatin analogues 
(SSAs), such as octreotide or lanreotide, are the most commonly used medications in patients 
with acromegaly. The current treatment goals in acromegaly are to reduce or control tumour 
growth, inhibit GH hypersecretion, and normalize IGF-1 levels, which help control disease 
complications, decrease mortality, and improve QoL [9]. However, the correlation between 
clinical severity and the impact of the disease perceived by patients is weak; thus, QoL should
be used as an additional outcome to incorporate the patient’s perspective [10].
Lanreotide autogel is a long-acting, super-saturated, viscous aqueous formulation of 
lanreotide injected subcutaneously once every 28–56 days [11, 12]. In treatment-naïve 
patients with acromegaly, lanreotide autogel improved their QoL [13]. In this real-world 
study, we investigated the effect of lanreotide autogel on QoL among patients who had been 
on this medication for up to three years. Moreover, we related QoL measures to hormonal and 
clinical variables.
Material and methods
Study design and setting
This prospective, non-interventional, observational, multi-centre cohort study was conducted 
at 37 centres in Poland from November 2014 to May 2018. Participants were enrolled over 18
months. After enrolment, participants were followed up for two years at six visits, 
approximately once every 4–5 months (V1–6). In this non-interventional study, lanreotide 
autogel 120 mg was administered and managed within routine care.
Participants
We included adult patients (aged > 18 years) with acromegaly, who had received treatment 
with lanreotide autogel 120 mg for ≥ 3 months and < 3 years. Exclusion criteria were as 
follows: active participation in any interventional or any other non-interventional acromegaly 
clinical study or any medical or psychological condition that compromised the ability to give 
informed consent. Participants were withdrawn if lanreotide autogel 120 mg was stopped or 
interrupted (i.e. changed for another lanreotide dose or to another SSA). Because this was a 
non-interventional study, no other withdrawal criteria were specified. Participants were free to
withdraw consent at any time. Data were collected up to the time of withdrawal. All patients 
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signed informed consent before enrolment. The study was approved by local Ethics 
Committees at each study site.
Assessments
Quality of life
Quality of life was measured with the Acromegaly Quality of Life (AcroQoL) questionnaire at
baseline and then at visits 2, 3, and 6. The AcroQoL questionnaire is a validated disease-
specific self-assessment questionnaire designed for use in clinical trials and everyday practice.
The AcroQoL questionnaire includes 22 items relating to two dimensions: physical (8 items) 
and psychological (14 items), the latter being divided into two subdimensions: psychological 
appearance (7 items) and psychological personal relations (7 items) [6]. Each AcroQoL item 
is answered on a five-point Likert scale. Moreover, during all study visits, participants gave 
an overall assessment of treatment satisfaction on a five-point Likert scale (1–5; completely 
satisfied, rather satisfied, neither satisfied nor dissatisfied, rather dissatisfied, and completely 
dissatisfied).
Clinical and ancillary assessments
At baseline, we collected demographic data, date of acromegaly diagnosis, details on current 
and prior acromegaly treatment (medications, radiation therapy, or surgery), and tumour 
presence and size (microadenoma [< 10 mm], macroadenoma [≥ 10 mm, < 40 mm], giant 
tumour [≥ 40 mm], no tumour). At every visit, we looked for predefined acromegaly 
symptoms (headache, sweating, joint symptoms, and swelling) and predefined comorbidities 
(altered carbohydrate metabolism, hypertension, sleep apnoea, heart disease, hypopituitarism, 
hyperprolactinaemia, hyperthyroidism, hypogonadism, nodular goitre, simplex goitre, and 
malignant tumour). The dose of lanreotide and the injection interval were recorded at every 
visit. The tumour size was assessed by magnetic resonance imaging at baseline. The serum 
concentrations of glucose, GH, and IGF-1 were measured at every visit in local laboratories. 
Hormonal control was defined as GH concentrations < 2.5 μg/L and IGF-1 concentrations 
within age- and sex-specific normal ranges [14]. Adverse events were recorded at every visit; 




No inferential statistical analyses were planned or performed. All data are presented 
descriptively overall and by subgroups. The enrolled population was defined as all 
participants who signed an informed consent form. The study population included participants
without major protocol deviations. As the primary endpoint, the AcroQoL total score, 
AcroQoL dimensions, and subdimensions scores were calculated per visit in the study 
population. The total AcroQoL score was obtained by adding scores from 22 items with the 
following formula:
 [(X – 22)/(110 – 22)]  100, 
with higher scores indicating better QoL [6]. Secondary endpoints included the control of 
clinical symptoms, hormonal control, treatment satisfaction, and AcroQoL scores by 
subgroups. It was planned to enrol 150 patients because this sample size was deemed 
necessary to describe QoL in the following subgroups: controlled/uncontrolled disease, 
with/without prior radiotherapy, with/without prior surgery.
Results
Participants
Of the 152 patients enrolled in the study, 128 were finally included in the study population (24
patients were excluded due to major protocol deviations), and 115 completed the study (Fig. 
1). The results presented herein are for the study population.
Patients had a long duration of acromegaly, with a median (95% confidence interval [CI]) 
time from diagnosis of 3.3 (2.8, 4.2) years. At baseline, 110 (86%) patients had symptoms of 
acromegaly. Most patients had headache (57%), sweating (58%), and joint symptoms (64%). 
Moreover, the comorbidity burden was high, with most patients having altered carbohydrate 
metabolism (56%), hypertension (60%), or nodular goitre (52%). At baseline, 74% of patients 
had visible pituitary tumours on magnetic resonance imaging. Hormonal control was achieved
in 27% of patients at baseline. Other baseline characteristics are presented in Table 1.
Sixty-nine per cent of patients received another acromegaly therapy before lanreotide autogel 
(including surgery [87.5%], radiation therapy [13.6%], and medications [34.1%]; Tab. 1). At 
baseline, patients had received lanreotide autogel for a median (95% CI) of 13.4 (9.9, 17.3) 
months. The interval of lanreotide autogel 120 mg injections and concomitant medications for
acromegaly at baseline are shown in Table 2.
Quality of life and satisfaction with treatment
The mean (95% CI) total AcroQoL score was 50.27 (47.25, 53.28) at baseline, and it did not 
change substantially during the study, with a mean increase from baseline to the end of the 
study of 1.21 (–1.39, 3.82) points. The mean (95% CI) AcroQoL physical dimension score 
was 48.76 (45.16, 52.37) at baseline, with a mean on-study increase of 1.08 (–2.09, 4.26). The
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mean (95% CI) AcroQoL psychological dimension score was 51.30 (48.20, 54.40) at baseline,
with a mean on-study increase of 1.21 (–1.43, 3.84). The mean (95% CI) AcroQoL 
psychological appearance subdimension score was 40.65 (37.47, 43.83) at baseline, with a 
mean on-study increase of 3.81 (1.18, 6.45). The mean (95% CI) AcroQoL psychological 
personal relations subdimension score was 62.53 (58.82, 66.24) at baseline, with a mean on-
study decrease of –1.38 (–4.65, 1.89). The mean AcroQoL scores are shown in Figure 2.
The total AcroQoL scores remained similar in patients with or without hormonal control, prior
acromegaly treatment, prior radiotherapy, and prior surgery (Fig. 3).
Treatment satisfaction
At baseline, 32% of patients were very satisfied with the treatment, 56% were satisfied, 10% 
were neither satisfied nor dissatisfied, and 2% were dissatisfied; none of them were very 
dissatisfied with the treatment. In 26% of patients, the satisfaction with treatment improved 
from baseline to the end of the study, in 62% of patients it did not change, and 12% showed a 
decrease in their satisfaction during the study.
Disease control and change in lanreotide dosing interval
The hormonal control status did not change in over 81% of patients, and 33% had hormonal 
control at the end of the study. Moreover, there was no change in clinical symptoms in over 
82% of patients from baseline to the end of study.
We found no change in the presence of comorbidities or complications related to acromegaly, 
including altered carbohydrate metabolism, hypertension, sleep apnoea, heart disease, 
hypopituitarism, hyperprolactinaemia, hyperthyroidism, simplex goitre, and malignant 
tumour, in over 91% of patients. There was also no change in the presence of hypogonadism 
in over 85% of patients or nodular goitre in over 83% of patients. Furthermore, there was no 
change in the presence of other comorbidities in more than 67% of patients.
Regarding lanreotide administration and dosing, 84% of patients in the study population did 
not change injection frequency from baseline to the end of the study, 63% of patients received
lanreotide autogel once every 28 days, 12% once every 42 days, and 9% once every 56 days. 
No shift in the mode of injection (i.e. self-injection or injection by healthcare professionals) 
was observed in the study population. Lanreotide autogel was injected by healthcare 
professionals in ≥ 96% of patients throughout the study. 
Adverse events
During the study, 15 adverse events associated or coinciding with study drug use (six serious, 
four non-serious, and five related to product administration) were reported in six participants 
from the enrolled population. Among the four non-serious adverse events, all were considered
to be related to the study medication (diarrhoea [two events], nausea, headache). Among the 
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six serious adverse events, three were considered possibly related to the study drug (diarrhoea,
acute cholecystitis, headache). None of the 15 adverse events were associated with a fatal 
outcome. Three patients died during the study (events not reported as serious adverse events 
as per study protocol): one death without any details provided, one death for cardiovascular 
reasons, and one death due to haemorrhagic stroke. No new safety findings or safety issues 
requiring further investigation were identified in this study.
Discussion
This real-world, prospective, longitudinal study carried out among patients who had a long 
duration of acromegaly found that global QoL and its physical and psychological aspects 
remained stable, whereas the AcroQoL psychological appearance subdimension improved 
numerically. Most patients were satisfied or very satisfied with the treatment (and no patients 
were very dissatisfied). Hormonal control and symptoms and complications of acromegaly 
did not change in most patients over the study. The safety findings were in line with the 
known safety profile of lanreotide.
Our study provides information on QoL in patients with a long duration of acromegaly. At 
baseline, the median time since diagnosis was over three years, and the median time of 
lanreotide autogel treatment was approximately one year, with most patients having received 
other acromegaly treatments. Approximately 60% of the 128 patients had headache and joint 
symptoms, which can reduce QoL in those with acromegaly [15]. Indeed, previous research 
showed that patients with acromegaly and joint pain had a substantially lower QoL (AcroQoL 
score, ~59) than those without joint pain (AcroQoL, ~76) [16]. Similarly, patients with 
acromegaly and spinal joint complaints scored lower than those without these comorbidities 
on several QoL questionnaires, including AcroQoL (~61 vs. ~71 points) [17]. Headaches are 
also associated with decreased QoL or no improvement in QoL among patients with 
acromegaly [18, 19].
Overall, the QoL in our cohort was substantially reduced, with a mean total AcroQoL score of
~50, which is lower than healthy people and patients with acromegaly from previous studies. 
For example, in a study from Romania, the mean total AcroQoL was ~76 in healthy people 
and 61 in patients with acromegaly [20]. In another study, among patients with a “severe” 
reduction of QoL, the mean total AcroQoL was higher than in our study (AcroQoL, ~57) [3]. 
Yet, a similar QoL to our cohort was observed among patients with long-lasting acromegaly 
(> 10 years) and a significant disease burden (AcroQoL, ~54), and it did not change over five 
years [21]. Similarly, after treatment of GH excess, Biermasz et al. found that 118 patients 
with acromegaly had persistently decreased QoL despite biochemical cure [22]. These 
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findings suggest that long-lasting acromegaly causes a sustained reduction of QoL, despite 
disease-specific treatment.
Although the total AcroQoL score did not change substantially in our cohort, the improvement
in the psychological dimension might be important to patients with acromegaly. Indeed, in a 
study that used AcroQoL to compare QoL between patients with acromegaly and people with 
obesity, the psychological appearance subdimension was the most reduced subscale in 
patients with acromegaly [23].
In a study among 90 treatment-naïve patients with acromegaly (mean disease duration of four 
months), who received lanreotide autogel 120 mg, Caron et al. found an improvement in all 
AcroQoL scores after one year of treatment (mean change of ~5% on the personal relations 
subdimension, ~10% in the total, physical, and psychological dimensions; and ~15% on the 
appearance subdimension) [24]. However, the difference in the characteristics of participants 
(i.e. the duration of acromegaly and type of treatment) could explain why the improvement in 
QoL was greater in the study by Caron et al. than in our study.
An improvement in QoL was also observed among 53 treatment-naïve patients with 
acromegaly, who received lanreotide autogel 120 mg (QoL assessed with the Nottingham 
questionnaire) [13]. In contrast, we found no change in QoL among patients in our cohort who
had been on lanreotide treatment for up to three years (median of approximately one year). 
Meanwhile, a small study showed that AcroQoL scores improved during four years in patients
who received octreotide [18]; however, this was a retrospective study that could have had 
selection bias (i.e. selective retainment of patients who perceived improvement). In line with 
this assumption, a 24-week prospective study found a modest improvement of QoL on 
octreotide only in the psychological subdimension, similarly to our study [25].
Similarly to most previous reports, we did not find that the hormonal status affected the QoL
[26]. QoL remained stable in our cohort regardless of baseline hormonal control status, prior 
surgery, prior radiotherapy, or lanreotide dosing interval. Likewise, Matta et al. found that 
QoL in patients with a mean duration of acromegaly of 10 years was similar regardless of 
hormonal control (AcroQoL, ~60) [27]. However, another study showed that QoL was higher 
(AcroQoL, ~61–71) among patients with long-lasting acromegaly (>10 years) who achieved 
hormonal control than that observed in our cohort [17]. Thus, the importance of hormonal 
control of acromegaly for QoL requires further investigation.
Our study was limited by a heterogeneous sample (disease duration, previous treatments), and
thus, the effect of lanreotide autogel treatment on QoL could be obscured by confounding 
factors. However, our study provides important real-world evidence that may be more 
relevant to clinical practice than the findings from clinical trials, in which only selected 
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patients, typically shortly after diagnosis, are followed for a limited time. Our cohort of 
patients reflected, for example, the high prevalence of comorbidities that are typically 
observed among patients with acromegaly [28]. The available evidence indicates that, in the 
long-term, acromegaly causes considerable problems that may not be directly related to the 
biological aspects of the disease. These problems include everyday challenges like a negative 
body image and major life changes, such as employment issues [2, 29]. Our study presents a 
picture of the most common symptoms and complications of acromegaly among patients in 
Poland. As in previous studies, most patients had joint symptoms, headache, and sweating
[30–32]. Arterial hypertension, altered glucose metabolism, and nodular goitre were also 
frequent [33, 34].
It is worth mentioning that despite the lack of improvement in symptoms and QoL, overall the
patients in this study were kept on the same therapy. A potential reason is that at the time of 
the study, there were only two long-acting SSAs available for acromegaly treatment in 
Poland: octreotide LAR and lanreotide autogel. Other treatment options, such as pasireotide (a
somatostatin analogue) and pegvisomant (a GH receptor antagonist), were not reimbursed at 
the time of the current study. Nonetheless, further symptomatic treatment, such as 
physiotherapy, offered in addition to disease-specific medications like lanreotide, could help 
improve QoL in patients with long-lasting acromegaly. Indeed, an interdisciplinary approach 
of treating the various comorbidities and symptoms present in patients with acromegaly seems
to be more effective than disease-specific treatment alone [35,36]. Evidence-based guidelines 
for the treatment of acromegaly complications (including cardiovascular, endocrine, 
metabolic, and oncologic comorbidities, sleep apnoea, and bone and joint disorders) have 
recently been produced by the Acromegaly Consensus Group, and they could assist in 
improving QoL among patients with acromegaly [37].
Conclusions
We found that QoL remains stable in patients with long-lasting acromegaly and a substantial 
disease burden during two years of treatment with lanreotide autogel. Despite good control of 
symptoms throughout the study, the total AcroQoL scores, including those of the AcroQoL 
physical and psychological dimensions, were unchanged. However, scores on the AcroQoL 
psychological appearance subdimension improved numerically, which is promising because 
this subscale is often significantly reduced in patients with acromegaly. Moreover, most 
patients remained satisfied with lanreotide autogel treatment during the study. Further studies 
into whether other interventions (like physiotherapy or the targeted treatment of acromegaly 
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complications) combined with lanreotide autogel therapy improve QoL in patients with long-
lasting acromegaly are warranted.
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Table 1. Baseline characteristics in the study population
 Study population 
(n =128)
Age, mean ± SD [years] 51.6 ± 13.5
Women, n (%) 71 (55.5)
Height, mean ± SD [cm] 172.5 ± 10.5
Weight, mean ± SD [kg] 89.3 ± 19.6
BMI, mean ± SD [kg/m²] 30.05 ± 6.40
Time since diagnosis [years], median (95% confidence interval) 3.3 (2.8, 4.2)
Clinical symptoms, n (%) 110 (85.9)
Headache 73 (57.0)
Sweating 74 (57.8)
Joint symptoms 82 (64.1)
Swelling 53 (41.4)
Comorbidities, n (%)
Altered carbohydrate metabolism 71 (55.5)
Hypertension 77 (60.2)
Sleep apnoea 45 (35.2)





Nodular goitre 66 (51.6)
Simplex goitre 8 (6.3)
Malignant tumours 6 (4.7)
Therapy before lanreotide autogel, n (%)
None 40 (31.3)
Previous surgery 77 (87.5)a
Previous radiation therapy 12 (13.6)a
Previous medications (n = 30), n (%)
Octreotide 





Tumour characteristics, n (%)




Giant tumour 2 (1.7)
GH, n (%)
< 2.5 µg/L 37 (51.4)
≥ 2.5 µg/L 35 (48.6)
IGF-1, n (%)
Normal range 37 (40.7)
Outside normal range 54 (59.3)
Hormonal controlc, n (%) 23 (27.4)
a — of previously treated patients; b — of patients receiving medications; c — growth 
hormone (GH) concentrations < 2.5 μg/L and insulin growth factor 1 (IGF-1) concentrations 
within age- and sex-specific normal ranges (as specified by Scacchi & Cavagnini [14]).
Table 2. Lanreotide autogel dosing interval and treatment duration and concomitant 
acromegaly medications at baseline
 Study population 
(n = 128)
Lanreotide autogel dosing interval, n (%)
28 days 96 (75.0)
42 days 22 (17.2)
56 days 10 (7.8)
Mode of injection, n (%)
Healthcare professional 124 (96.9)
Patient self-injection 4 (3.1)
Duration of lanreotide autogel treatment (months), median 
(95% confidence interval)
13.4 (9.9, 17.3)










24 patients excluded due to 26 major protocol deviations
• Patient discontinued treatment but not withdrawn (n = 13)
• Lanreotide autogel was stopped/interrupted but patient not withdrawn (n = 6)
• Missing AcroQoL score at baseline or at visit 2 or 3 and 6 (n = 5) 
• Did not meet entry criteria (n = 2)
14
Figure 2. Mean Acromegaly Quality of Life Questionnaire (AcroQoL) scores for the study 
population at visits (V) 1, 2, 3, and 6. Total AcroQoL scores (A), physical dimension (B), 
psychological dimension (C), psychological appearance subdimension (D), and psychological
personal relations subdimension (E). Data are presented as means (95% confidence interval 
[CI])
Figure 3. Mean Acromegaly Quality of Life Questionnaire (AcroQoL) scores for the study 
population at visits (V) 1, 2, 3, and 6 according to hormonal control (A), prior acromegaly 
treatment (B), prior radiotherapy (C), prior surgery (D), and lanreotide autogel dosing interval
(E). Data are presented as means (95% confidence interval [CI])
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